DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Ohki T, Isogawa A, Toda N. et al.
Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors.
Clin Drug Investig 2016;
36: 313-319
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.